Nemucore Medical Innovations, Inc.
Developing life saving Precision Medicines for the treatment of Acute Myeloid Leukemia & Ovarian Cancer. Leveraging >$37M in non-dilutive product funding.
Nemucore Medical Innovations, Inc. is dedicated to the development and commercialization of life-saving Precision Medicines for the treatment of multi-drug resistant cancers, particularly Ovarian Cancer, Acute Myeloid Leukemia as well as TNBC and MDS.
Our leading clinical candidate NMI-900 and its companion diagnostic are ready to enter clinical trials for AML at Memorial Sloan Kettering Cancer Center and Moffitt Cancer Center.